Evidence map›Paper›PMID 33328623›Full record

ArticleScientific reports2020

National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017.

Cristina Bosetti, Eugenio Traini, Tahiya Alam, Christine A Allen, Giulia Carreras, Kelly Compton, Christina Fitzmaurice, Lisa M Force, Silvano Gallus, Giuseppe Gorini and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Cristina BosettiDepartment of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan, Italy. cristina.bosetti@marionegri.it.
Eugenio TrainiClinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
Tahiya AlamInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Christine A AllenInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Giulia CarrerasOncologic Network, Prevention, and Research Institute, Florence, Italy.
Kelly ComptonInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Christina FitzmauriceInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Lisa M ForceDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Silvano GallusDepartment of Environmental Health Sciences, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Giuseppe GoriniOncologic Network, Prevention, and Research Institute, Florence, Italy.
James D HarveyInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Jonathan M KocarnikInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Carlo La VecchiaDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Alessandra LugoDepartment of Environmental Health Sciences, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Mohsen NaghaviInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Alyssa PenniniInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Cristiano PiccinelliCPO Piemonte, AOU Città Della Salute E Della Scienza, Torino, Italy.
Luca RonfaniClinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
Rixing XuInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Lorenzo MonastaClinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
Institute for Health Metrics and Evaluation · USIRCCS Materno Infantile Burlo Garofolo · ITMario Negri Institute for Pharmacological Research · ITUniversity of Washington · USAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITFred Hutch Cancer Center · USSt. Jude Children's Research Hospital · USUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We monitored the burden of cancer in Italy and its trends over the last three decades, providing estimates of cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs), for cancer overall and 30 cancer sites using data from the Global Burden of Disease study 2017. An overview of mortality trends between 1990 and 2017 was also provided. In 2017, there were 254,336 new cancer cases in men and 214,994 in women, corresponding to an age-standardized incidence rate (ASIR) of 438 and 330/100,000, respectively. Between 1990 and 2017, incident cancer cases, and, to a lesser extent, ASIRs significantly increased overall and for almost all cancer sites, but ASIRs significantly declined for lung and other tobacco-related neoplasms. In 2017, there were 101,659 cancer deaths in men (age-standardized death rate, ASDR, 158.5/100,000) and 78,918 in women (ASDR 93.9/100,000). Cancer deaths significantly increased between 1990 and 2017 (+ 18%), but ASDR significantly decreased (- 28%). Deaths significantly increased for many cancer sites, but decreased for stomach, esophageal, laryngeal, Hodgkin lymphoma, and testicular cancer. ASDRs significantly decreased for most neoplasms, with the main exceptions of cancer of the pancreas and uterus, and multiple myeloma. In 2017, cancer caused 3,204,000 DALYs. Between 1990 and 2017, DALYs and age-standardized DALY rates significantly declined (-3.4% and -33%, respectively). Age-standardized mortality rates in Italy showed favorable patterns over the last few decades. However, the absolute number of cancer cases and, to a lower extent, of cancer deaths increased likely due to the progressive ageing of the population, this calling for a continuous effort in cancer prevention, early diagnosis, and treatment.

Indexed as

Cost of IllnessAdultAgedEarly Detection of CancerFemaleHumansItalyMaleMiddle AgedNeoplasmsNeoplasms, Germ Cell and EmbryonalQuality-Adjusted Life YearsRisk FactorsTesticular Neoplasms

Identifiers

PMID33328623
PMCPMC7744506
OpenAlexW3111928690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.